Results 31 to 40 of about 765,112 (149)

Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are a relatively new class of drugs that were initially approved by the US Food and Drug Administration to improve glycemic control in patients with type 2 diabetes mellitus and, subsequently, weight reduction in patients with obesity.
Audrey Y. Chang, Farrah J. Mateen
wiley   +1 more source

Deep evolutionary conservation of an intramolecular protein kinase activation mechanism [PDF]

open access: yes, 2012
DYRK-family kinases employ an intramolecular mechanism to autophosphorylate a critical tyrosine residue in the activation loop. Once phosphorylated, DYRKs lose tyrosine kinase activity and function as serine/threonine kinases.
Cleghon Vaughn   +31 more
core   +1 more source

Single‐Cell Transcriptomic Profiling Identifies B Cell‐Intrinsic Dysregulation of Sphingolipid Biosynthesis and Could Be Improved by Inhibiting UGCG in Primary Immune Thrombocytopenia

open access: yesAdvanced Science, EarlyView.
This study generates the single‐cell atlas of pathogenic B‐cell subset Bc‐5 in ITP. It identifies RUNX3 as a key survival regulator and uncovers sphingolipid‐driven metabolic reprogramming, validating UGCG inhibition as a therapeutic candidate and building a valuable resource for ITP mechanistic and therapeutic exploration.
Dongmei Luo   +10 more
wiley   +1 more source

Chromosomal Abnormalities, Drug Sensitivity and Resistance in Hematological Malignancies: A Comprehensive Overview by the Francophone Group of Hematological Cytogenetics (GFCH)

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Chromosomal abnormalities have a major clinical impact on hematological malignancies, particularly with regard to treatment strategies. To preserve and consolidate fundamental knowledge in this rapidly evolving field, the Francophone Group of Hematological Cytogenetics (Groupe Francophone de Cytogénétique Hématologique, GFCH) conducted a ...
Florence Nguyen‐Khac   +16 more
wiley   +1 more source

Additional file 3: of KinMutRF: a random forest classifier of sequence variants in the human protein kinase superfamily

open access: yes, 2016
Supplementary File S3. KinMutRF predictions on the human Bruton agammaglobulinemia tyrosine kinase domain.
Jose Izarzugaza (3544625)   +5 more
core   +1 more source

Final Analysis of the BRUIN Phase 1/2 Study Assessing the Safety and Efficacy of Pirtobrutinib Monotherapy in Patients With MCL

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Pirtobrutinib, a highly selective, non‐covalent Bruton tyrosine kinase inhibitor (BTKi) previously demonstrated durable efficacy and tolerable safety following covalent (c) BTKi therapy in heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL).
Michael L. Wang   +36 more
wiley   +1 more source

The synergistic impact of granulocytic myeloid‐derived suppressor cells and innate lymphoid cells in systemic sclerosis

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Systemic sclerosis (SSc) is a chronic autoimmune disorder characterized by immune dysregulation and fibrosis, with myeloid‐derived suppressor cells (MDSCs) emerging as important regulators of immune responses. However, the role of MDSCs in SSc‐associated fibrosis and their interactions with other immune cell populations remain poorly ...
Stefanie Weber   +15 more
wiley   +1 more source

Population pharmacokinetics and exposure–response analysis of acalabrutinib in patients with untreated mantle cell lymphoma in the ECHO trial

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims The phase 3 ECHO trial demonstrated superior progression‐free survival (PFS) with acalabrutinib plus bendamustine‐rituximab (BR) versus placebo plus BR in treatment‐naive (TN) mantle cell lymphoma (MCL). This analysis characterizes the pharmacokinetic (PK) profile of acalabrutinib and ACP‐5862 (active metabolite) when administered with BR and ...
Damilola Olabode   +7 more
wiley   +1 more source

Complex formation of EphB1/Nck/Caskin1 leads to tyrosine phosphorylation and structural changes of the Caskin1 SH3 domain. [PDF]

open access: yes, 2012
Scaffold proteins have an important role in the regulation of signal propagation. These proteins do not possess any enzymatic activity but can contribute to the formation of multiprotein complexes.
Roopesh Udupa   +16 more
core   +1 more source

Home - About - Disclaimer - Privacy